Lee Pharmaceuticals, Inc. (LPHM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lee Pharmaceuticals, Inc. (LPHM) trades at $0.099. Lee Pharmaceuticals, Inc. operates within the financial services sector as a shell company, focusing on the manufacturing of personal care and cosmetic products. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for LPHM: LPHM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LPHM against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on LPHM.
How is this calculated? →Lee Pharmaceuticals, Inc. (LPHM) Financial Services Profile
Lee Pharmaceuticals, Inc., established in 1971, operates as a shell company within the financial services sector, manufacturing personal care and cosmetic products. Trading on the OTC market, the company faces liquidity and disclosure challenges, reflected in its negligible market cap and negative price-to-earnings ratio, indicating potential financial instability.
What Is the Investment Thesis for LPHM?
Investing in Lee Pharmaceuticals, Inc. (LPHM) presents substantial risks due to its status as a shell company operating on the OTC market. With a market capitalization of $0.00B and a negative P/E ratio of -59.22, the company's financial health is questionable. The high beta of 158.41 indicates extreme volatility. Potential catalysts are speculative, hinging on successful restructuring or acquisition. The primary value driver would be a turnaround in operational performance, which is currently unsupported by available data. Investors should approach LPHM with extreme caution, considering the lack of liquidity, limited financial disclosure, and inherent risks associated with OTC-listed shell companies. There is no dividend yield.
Based on FMP financials and quantitative analysis
LPHM Key Highlights
Market capitalization of $0.00B indicates a very small or non-existent valuation.
- Negative P/E ratio of -59.22 suggests the company is not profitable.
- Beta of 158.41 indicates extremely high volatility compared to the market.
- Operates as a shell company, implying limited active business operations.
- Listing on the OTC market signifies higher risk and lower regulatory oversight.
Who Are LPHM's Competitors?
LPHM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LPHM's Key Strengths?
Established manufacturing capabilities.
- Long operating history since 1971.
- Diversified product range in personal care and cosmetics.
What Are LPHM's Weaknesses?
Negligible market capitalization.
- Negative P/E ratio indicating lack of profitability.
- High beta indicating extreme volatility.
- Listing on the OTC market signifies higher risk.
What Could Drive LPHM Stock Higher?
Potential restructuring initiatives to improve operational efficiency.
- Possibility of acquisition or merger by another company.
- Efforts to expand private label and contract manufacturing services.
- Development of online sales channels to reach a broader customer base.
- Introduction of new product lines to meet evolving consumer demands.
What Are the Key Risks for LPHM?
Financial-distress signal — its Altman Z-Score of -3.03 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-69.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Limited financial disclosure and transparency due to OTC listing.
- Low liquidity and high volatility in trading volume.
- Intense competition in the personal care and cosmetics market.
- Regulatory scrutiny of shell companies and potential delisting.
- Economic downturn affecting consumer spending on personal care products.
What Are the Growth Opportunities for LPHM?
- Restructuring and Operational Turnaround: Lee Pharmaceuticals could explore a comprehensive restructuring plan to revitalize its operations and improve financial performance. This would involve streamlining product lines, enhancing marketing efforts, and securing strategic partnerships. Successful execution could lead to increased revenue and improved profitability, potentially attracting investor interest. However, the timeline for such a turnaround is uncertain, and the company faces significant competition from established players in the personal care and cosmetics market.
- Acquisition or Merger: As a shell company, Lee Pharmaceuticals could be an attractive target for acquisition or merger by another entity seeking a public listing or specific assets. A successful acquisition could provide a significant return for current shareholders. However, the likelihood of such an event is speculative and depends on various factors, including market conditions and the company's attractiveness to potential acquirers. The timeline for a potential acquisition is unpredictable.
- Private Label and Contract Manufacturing Expansion: Lee Pharmaceuticals could focus on expanding its private label and contract manufacturing services. This would involve targeting small to medium-sized businesses that require manufacturing support for their personal care and cosmetic products. By leveraging its existing manufacturing capabilities, the company could generate additional revenue streams. The success of this strategy depends on its ability to secure new contracts and maintain competitive pricing. The timeline for significant expansion is estimated at 2-3 years.
- Online Sales Channel Development: Lee Pharmaceuticals could invest in developing a robust online sales channel to reach a broader customer base. This would involve creating an e-commerce platform, implementing digital marketing strategies, and optimizing the customer experience. A successful online sales channel could drive revenue growth and improve brand visibility. However, the company faces competition from established online retailers and requires significant investment in technology and marketing. The timeline for significant online sales growth is estimated at 1-2 years.
- New Product Development: Lee Pharmaceuticals could invest in developing innovative personal care and cosmetic products to meet evolving consumer demands. This would involve conducting market research, identifying unmet needs, and formulating new products that offer unique benefits. Successful new product launches could drive revenue growth and enhance the company's competitive position. However, the company faces challenges related to research and development costs, regulatory approvals, and market acceptance. The timeline for new product development and launch is estimated at 1-2 years.
What Are LPHM's Competitive Advantages?
- Established manufacturing capabilities in personal care and cosmetic products.
- Long-standing presence in the market since 1971.
- Private label and contract manufacturing services offer diversification.
What Does LPHM Do?
Lee Pharmaceuticals, Inc., incorporated in 1971 and based in South El Monte, California, operates as a manufacturer of personal care and cosmetic products. The company's product line includes a variety of items such as lip balm, nasal sprays, nail care products, depilatories, and smoking cessation aids. Their broader product categories encompass aloe vera products, antacids, baby care items, cosmetics, cough and cold remedies, depilatories, laxatives, men's personal care products, oral care solutions, pain relievers, skincare products, tobacco accessories, topical treatments, and nutritional supplements. Lee Pharmaceuticals also provides private label and contract manufacturing services, catering to retailers and wholesalers, and offering products through online channels. Despite its long history, the company's current financial metrics, including a market capitalization of $0.00B and a negative P/E ratio of -59.22, suggest significant financial challenges. The company's operations are managed by a small team, with Ronal Ford at the helm, overseeing a single employee. The company's OTC listing further underscores the speculative nature of its stock.
What Products and Services Does LPHM Offer?
- Manufactures personal care products such as lip balm and nasal sprays.
- Produces cosmetic products including nail care and depilatories.
- Offers smoking cessation aids.
- Provides aloe vera products, antacids, and baby care items.
- Creates cough and cold remedies, laxatives, and pain relievers.
- Supplies skincare products, tobacco accessories, and topical treatments.
- Offers vitamins and nutritional items.
- Provides private label and contract manufacturing services.
How Does LPHM Make Money?
- Manufacturing and selling personal care and cosmetic products.
- Providing private label manufacturing services to other companies.
- Generating revenue through retail, wholesale, and online sales channels.
What Industry Does LPHM Operate In?
Lee Pharmaceuticals, Inc. operates within the shell company segment of the financial services industry. This segment is characterized by companies with limited operations and high levels of speculation. The OTC market, where LPHM is listed, is known for its less stringent listing requirements and higher risk profiles compared to major exchanges. The competitive landscape includes other OTC-listed entities, many of which face similar challenges related to liquidity, disclosure, and operational viability. The overall market trend shows increasing scrutiny of shell companies due to regulatory concerns and investor protection.
Who Are LPHM's Key Customers?
- Retailers who stock personal care and cosmetic products.
- Wholesalers who distribute these products to various outlets.
- Consumers who purchase the products directly through online channels.
- Companies seeking private label manufacturing services.
Financial Health
Lee Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.03 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Lee Pharmaceuticals, Inc. stands at -69.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -4.3%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Lee Pharmaceuticals, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in South El Monte, US. The company is led by CEO Ronal Ford. LPHM has traded publicly since 1973.
LPHM Financials
Bull Case vs Bear Case
Bull Case
- Established manufacturing capabilities.
- Long operating history since 1971.
- Diversified product range in personal care and cosmetics.
- Upcoming: Potential restructuring initiatives to improve operational efficiency.
Bear Case
- Negligible market capitalization.
- Negative P/E ratio indicating lack of profitability.
- High beta indicating extreme volatility.
- Listing on the OTC market signifies higher risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
LPHM Latest News
No recent news available for LPHM.
LPHM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LPHM.
Price Targets
Wall Street price target analysis for LPHM.
LPHM MoonshotScore
What does this score mean?
The MoonshotScore rates LPHM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Ronal Ford
CEO
Ronal Ford serves as the CEO of Lee Pharmaceuticals, Inc., managing a small team. Information on Ford's prior experience and educational background is not available. His leadership is focused on navigating the challenges faced by the company, including its financial constraints and operational limitations. His role involves overseeing the manufacturing and distribution of personal care and cosmetic products, as well as exploring potential growth opportunities.
Track Record: Due to the limited available information and the company's current financial status, it is difficult to assess Ronal Ford's track record. Key milestones and strategic decisions under his leadership are not publicly documented. The company's performance, as reflected in its market capitalization and profitability, suggests significant challenges remain.
LPHM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lee Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting. This tier is generally considered the most speculative and carries the highest risk for investors compared to NYSE/NASDAQ-listed companies, which have stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of transparency due to limited or absent financial reporting.
- Low Liquidity: Difficulty in buying or selling shares due to minimal trading volume.
- High Volatility: Significant price swings due to speculative trading and lack of institutional interest.
- Potential for Fraud or Manipulation: Increased risk of fraudulent activities or market manipulation due to less regulatory oversight.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial constraints.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the background and experience of the company's management team.
- Evaluate the company's business model and competitive position.
- Understand the risks associated with investing in OTC-listed companies.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal disputes involving the company.
- Long operating history since 1971 (though current operations may be limited).
- Manufacturing capabilities in personal care and cosmetic products.
- Provision of private label and contract manufacturing services.
Lee Pharmaceuticals, Inc. Financial Services Stock: Key Questions Answered
What does Lee Pharmaceuticals, Inc. do?
Lee Pharmaceuticals, Inc. operates as a shell company that manufactures personal care and cosmetic products. Its product range includes items like lip balm, nasal sprays, and skincare products, sold through retailers, wholesalers, and online channels. The company also offers private label and contract manufacturing services.
What do analysts say about LPHM stock?
Currently, there is no available analyst coverage for Lee Pharmaceuticals, Inc. (LPHM) due to its status as an OTC-listed shell company with a negligible market capitalization. Key valuation metrics such as price-to-earnings ratio are negative, reflecting the company's lack of profitability. Given the limited financial disclosure and high-risk nature of OTC stocks, investors should conduct thorough due diligence and consider the potential for significant volatility and limited liquidity.
What are the main risks for LPHM?
The primary risks for Lee Pharmaceuticals, Inc. (LPHM) include its status as a shell company with limited operations and financial transparency. As an OTC-listed entity, it faces higher regulatory scrutiny and potential delisting. The company's negligible market capitalization and negative P/E ratio indicate financial instability. Low trading volume and high volatility further increase the risk for investors.
What are the key factors to evaluate for LPHM?
Evaluate LPHM on fundamentals, analyst consensus, and risk factors. Investing in Lee Pharmaceuticals, Inc. (LPHM) presents substantial risks due to its status as a shell company operating on the OTC market. Not financial advice.
How frequently does LPHM data refresh on this page?
LPHM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LPHM's recent stock price performance?
Lee Pharmaceuticals, Inc. (LPHM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established manufacturing capabilities. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LPHM overvalued or undervalued right now?
Lee Pharmaceuticals, Inc. (LPHM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LPHM before investing?
Before investing in Lee Pharmaceuticals, Inc. (LPHM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and lack of financial disclosures.
- AI analysis is pending, and further insights may be available in the future.